Improvements in human immunodeficiency virus-associated mortality make it difficult to deny transplantation based upon futility.
Outcomes in the current management era are unknown.
Dr Roland and colleagues from California, USA evaluated a prospective series of liver or kidney transplant recipients with stable human immunodeficiency virus disease.
|1-year liver recipients' survival was 91%|
|American Journal of Transplantation|
The research team assessed 11 liver, and 18 kidney transplant recipients for a median of 3 years.
The team found that 1- and 3-year liver recipients' survival was 91% and 64%, respectively.
The team noted that kidney recipients' survival was 94%.
The 1- and 3-year liver graft survival was 82% and 64%, respectively, and kidney graft survival was 83%.
The team found that kidney patient and graft survival were similar to the general transplant population.
However, liver survival was similar to the older population, based on 1999 to 2004 transplants in the national database.
CD4+ T-cell counts, and human immunodeficiency virus RNA levels were stable.
The researchers noted 2 opportunistic infections.
The researchers found that the 1- and 3-year cumulative incidence of rejection episodes for kidney recipients was 52%, and 70%, respectively.
About 75% of Hepatitis C virus-infected patients, but no patient with Hepatitis B virus infection, had recurrence.
Dr Roland's team concluded, "We observed good transplant and human immunodeficiency virus-related outcomes among kidney transplant recipients."
"Reasonable outcomes among liver recipients suggest that transplantation is an option for selected human immunodeficiency virus-infected patients cared for at centers with adequate expertise."